Evidence map›Paper›PMID 30773685›Full record

ArticleClinical transplantation2019

Transplant community perceptions of the benefits and drawbacks of alternative quality metrics for regulation.

Sarah E Van Pilsum Rasmussen, Sheng Zhou, Alvin G Thomas, Dorry L Segev, Lauren H Nicholas

Open access · greenAbstract read
In one paragraph

Article in Clinical transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarah E Van Pilsum RasmussenDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4644-3590
Sheng ZhouDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Alvin G ThomasDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4911-8192
Dorry L SegevDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lauren H NicholasDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Johns Hopkins University · USBloomberg (United States) · US

Funding

Long-Term Health Outcomes After Live Kidney Donation in African AmericansR01DK096008 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SEGEV, DORRY L. · 2013 to 2017
$3.8M
Patient Oriented Research in Solid Organ TransplantationK24AI144954 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SEGEV, DORRY L. · 2020 to 2024
$956k
Patient Oriented Research in Kidney Disease and Transplant SurgeryK24DK101828 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SEGEV, DORRY L. · 2014 to 2018
$922k
Geographic Variation in the Health and Economic Determinants and Outcomes of ElecK01AG041763 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NICHOLAS, LAUREN HERSCH · 2012 to 2016
$622k
NIAID NIH HHS K24 AI144954NIA NIH HHS K01 AG041763NIDDK NIH HHS K24 DK101828NIDDK NIH HHS R01 DK096008
6 · The paper itself

Abstract

backgroundThere is concern that the metrics currently used to regulate transplant centers, one-year patient and graft survival, may have adverse consequences including decreasing higher risk donor organ acceptance and transplant volume. This raises questions about whether alternative measures would be more appropriate.

methodsWe surveyed American Society of Transplant Surgeons (ASTS) and American Society of Transplantation (AST) members (n = 270) to characterize perceptions of several metrics that are used for regulation, are publicly reported, or have been suggested elsewhere, regarding their effectiveness, amenability to risk adjustment, and predicted effects on volume, mortality, and waitlist size.

resultsRespondents rated one-year patient and graft survival the most effective measure of quality of care (mean scores = 7.44, 7.31, respectively, out of 10) and most amenable to risk adjustment (mean scores = 6.26, 6.13, respectively). Most respondents believed alternative metrics would not impact their center's volume, waitlist size, or one-year transplant mortality. However, some did predict unintended consequences; for example, some believed using one-year waitlist mortality, one-year mortality of patients listed, or one-year mortality of patients referred for transplant would decrease the number of transplants performed (48.6%, 46.7%, and 48.3% of respondents, respectively). DISCUSSION: Despite previously published concerns with existing regulatory metrics, most participants did not believe any metrics would outperform one-year patient and graft survival.

Indexed as

Health Plan ImplementationBenchmarkingGraft SurvivalHumansOrgan TransplantationPrognosisQuality of Health CareRisk FactorsTime FactorsTissue and Organ ProcurementWaiting ListsinsuranceScientific Registry for Transplant Recipientssurvey

Identifiers

PMID30773685
PMCPMC6465095
OpenAlexW2917256903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.